The disclosure provides buprenorphine formulations that produce therapeuticplasmaconcentration levels of buprenorphine in patients to treat opioid usedisorder, to reduce oreliminate opioid withdrawal symptoms, to reduce or eliminate opioid craving,and to induce andmaintain opioid abstinence.